Research Antibodies

 
News Articles for Research Antibodies top ^
Vaccinated Animals Generated a Broad Spectrum of Protective Antibodies Vaccine Induces Antibodies that are at Least as Protective as Palivizumab Palivizumab Competing Antibody Response from Vaccine Protects Against Both Homologous and Heterologous Disease Strains GAITHERSBURG, Md., Oct.
Sign-up for Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies investment picks
Multiple T-cell engaging bispecific programs show potential as disease modifying treatments for acute myelogenous leukemia, B-cell lymphomas and leukemia, and multiple myeloma Xencor designates its first bispecific antibody candidate, XmAb14045 an anti-CD123xCD3, for IND-enabling studies MONROVIA, Calif.
Sign-up for Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting investment picks
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, California, December 6-9, 2014, highlighting the following: “Antibody-drug conjugates represent an innovative and important therapeutic approach to targeting cancer.
Sign-up for Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from two ongoing phase 1 clinical trials evaluating SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA December 6-9, 2014.
Sign-up for Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting investment picks
2014/10/21
Amorfix closes private placement and receives back rights for ALS antibody therapeutic development and commercialization Canada NewsWire TORONTO , Oct.
Sign-up for Amorfix closes private placement and receives back rights for ALS antibody therapeutic development and commercialization investment picks
--Candidate Will Target Two Undisclosed Immune Checkpoints --Anti-TIM-3 Antibody Data to be Presented Today at the AACR Conference in Orlando WALTHAM, Mass.
Sign-up for TESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel Bispecific Antibody Candidate investment picks
CAMBRIDGE, Mass., Sept.
Sign-up for Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibodies From AnaptysBio investment picks
REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent in the U.S. investment picks
GAITHERSBURG, Md., Sept.
Sign-up for Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at ICAAC investment picks
BARCELONA, Spain, Nov.
Sign-up for Immunomedics Presents Clinical Data on Novel Antibody-Drug Conjugates for Solid Cancer Therapy investment picks
-- T-cell Killing of Human Gastric and Pancreatic Cancer Cell Lines Enhanced With Interferon-α --
Sign-up for Immunomedics Publishes Results on Immunotherapy of Solid Cancers Mediated by a Novel Bispecific Antibody investment picks
http://media.marketwire.com/attachments/201203/41309_medivation_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1153765&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA and YAVNE, ISRAEL --
Sign-up for Medivation Inc. Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd. for Potential Applications in Oncology investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Antibodies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Analysts  |  Next: Research Applications